OncoVax-P liposomal vaccine based on recombinant prostate specific antigen data

Jenner announced results from four Phase I/II studies, showing good tolerability, and clinical benefit in half of the patients. An immune response was

Read the full 238 word article

How to gain access

Continue reading with a
two-week free trial.